Ahmad N Fasseeh1,2, Baher Elezbawy3, Nada Korra1, Mohamed Tannira4, Hala Dalle5, Sandrine Aderian6, Sherif Abaza7, Zoltán Kaló8,9. 1. Syreon Middle East, Alexandria, Egypt. 2. Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. 3. Syreon Middle East, Alexandria, Egypt. baher.elezbawy@syreon.eu. 4. AbbVie BioPharmaceuticals, Dubai, United Arab Emirates. 5. AbbVie BioPharmaceuticals, Kuwait City, Kuwait. 6. AbbVie BioPharmaceuticals, Beirut, Lebanon. 7. Syreon Middle East, Cairo, Egypt. 8. Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary. 9. Syreon Research Institute, Budapest, Hungary.
Abstract
INTRODUCTION: Although previously regarded as a children's disease, it is clear that atopic dermatitis (AD) is also highly prevalent in adults. Because AD is not associated with mortality, it is usually neglected compared with other, fatal diseases. However, several studies have highlighted that AD burden is significant due to its substantial humanistic burden and psychosocial effects. This study aims to summarize and quantify the clinical, economic, and humanistic burden of AD in adults and adolescents. METHODS: A systematic literature search was performed in PubMed, Scopus, Cochrane, Centre for Reviews and Dissemination (CRD), EconPapers, The Professional Society for Health Economics and Outcomes Research (ISPOR), The National Institute for Health and Care Excellence (NICE), and The Canadian Agency for Drugs and Technologies in Health (CADTH). Studies were included if they reported clinical, economic, or humanistic effects of AD on adults or adolescents, from January 2011 to December 2020. The Grading of Recommendations Assessment tool was used to assess risk of bias for the included studies. Regression models were used to explain the correlation between factors such as disease severity and quality of life (QoL). RESULTS: Among 3400 identified records, 233 studies were included. Itch, depression, sleep disturbance, and anxiety were the most frequently reported parameters related to the clinical and humanistic burden of AD. The average utility value in studies not stratifying patients by severity was 0.779. The average direct cost of AD was 4411 USD, while the average indirect cost was 9068 USD annually. CONCLUSIONS: The burden of AD is significant. The hidden disease burden is reflected in its high indirect costs and the psychological effect on QoL. The magnitude of the burden is affected by the severity level. The main limitation of this study is the heterogeneity of different studies in terms of data reporting, which led to the exclusion of potentially relevant data points from the summary statistics.
INTRODUCTION: Although previously regarded as a children's disease, it is clear that atopic dermatitis (AD) is also highly prevalent in adults. Because AD is not associated with mortality, it is usually neglected compared with other, fatal diseases. However, several studies have highlighted that AD burden is significant due to its substantial humanistic burden and psychosocial effects. This study aims to summarize and quantify the clinical, economic, and humanistic burden of AD in adults and adolescents. METHODS: A systematic literature search was performed in PubMed, Scopus, Cochrane, Centre for Reviews and Dissemination (CRD), EconPapers, The Professional Society for Health Economics and Outcomes Research (ISPOR), The National Institute for Health and Care Excellence (NICE), and The Canadian Agency for Drugs and Technologies in Health (CADTH). Studies were included if they reported clinical, economic, or humanistic effects of AD on adults or adolescents, from January 2011 to December 2020. The Grading of Recommendations Assessment tool was used to assess risk of bias for the included studies. Regression models were used to explain the correlation between factors such as disease severity and quality of life (QoL). RESULTS: Among 3400 identified records, 233 studies were included. Itch, depression, sleep disturbance, and anxiety were the most frequently reported parameters related to the clinical and humanistic burden of AD. The average utility value in studies not stratifying patients by severity was 0.779. The average direct cost of AD was 4411 USD, while the average indirect cost was 9068 USD annually. CONCLUSIONS: The burden of AD is significant. The hidden disease burden is reflected in its high indirect costs and the psychological effect on QoL. The magnitude of the burden is affected by the severity level. The main limitation of this study is the heterogeneity of different studies in terms of data reporting, which led to the exclusion of potentially relevant data points from the summary statistics.
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann Journal: BMJ Date: 2008-04-26
Authors: Torsten Zuberbier; Seth J Orlow; Amy S Paller; Alain Taïeb; Roger Allen; José M Hernanz-Hermosa; Jorge Ocampo-Candiani; Margaret Cox; Joanne Langeraar; Jan C Simon Journal: J Allergy Clin Immunol Date: 2006-05-02 Impact factor: 10.793
Authors: J Ring; A Zink; B W M Arents; I A Seitz; U Mensing; M C Schielein; N Wettemann; G de Carlo; A Fink-Wagner Journal: J Eur Acad Dermatol Venereol Date: 2019-06-06 Impact factor: 6.166
Authors: Hywel Williams; Alistair Stewart; Erika von Mutius; William Cookson; H Ross Anderson Journal: J Allergy Clin Immunol Date: 2007-12-21 Impact factor: 10.793
Authors: M R Laughter; M B C Maymone; S Mashayekhi; B W M Arents; C Karimkhani; S M Langan; R P Dellavalle; C Flohr Journal: Br J Dermatol Date: 2020-11-29 Impact factor: 9.302
Authors: Brecht Devleesschauwer; Charline Maertens de Noordhout; G Suzanne A Smit; Luc Duchateau; Pierre Dorny; Claudia Stein; Herman Van Oyen; Niko Speybroeck Journal: BMC Public Health Date: 2014-11-21 Impact factor: 3.295
Authors: Matthew J Page; Joanne E McKenzie; Patrick M Bossuyt; Isabelle Boutron; Tammy C Hoffmann; Cynthia D Mulrow; Larissa Shamseer; Jennifer M Tetzlaff; Elie A Akl; Sue E Brennan; Roger Chou; Julie Glanville; Jeremy M Grimshaw; Asbjørn Hróbjartsson; Manoj M Lalu; Tianjing Li; Elizabeth W Loder; Evan Mayo-Wilson; Steve McDonald; Luke A McGuinness; Lesley A Stewart; James Thomas; Andrea C Tricco; Vivian A Welch; Penny Whiting; David Moher Journal: BMJ Date: 2021-03-29